Comparison between Ologen implant and different concentrations of MMC as an adjuvant to trabeculectomy
Session Details
Session Title: Presented Poster Session: Glaucoma
Venue: Poster Village: Pod 2
First Author: : Z.Eldaly EGYPT
Co Author(s): : A. Maasoud M. Saad A. Mohamed
Abstract Details
Purpose:
To establish efficacy and safety of Ologen collagen implant versus different concentrations of Mitomycin C (MMC) in trabeculectomy.
Setting:
A prospective interventional open-label study was conducted in the Department of Ophthalmology, Assiut University, Egypt from May 2014 till August 2016.
Methods:
Patients with POAG, PNAG and secondary OAG were assigned equally either to Trabeculectomy augmented by Ologen implant, 0.4 mg/mL or 0.2 mg/mL MMC. Complete success was considered when IOP ≤ 15 mmHg, incomplete success when IOP ˃ 15 mmHg and ≥ 21 mmHg and failure when IOP ˃ 21 mmHg. Study outcome measures were reduction in intra-ocular pressure (IOP), success rates, survival analysis and rate of complications.
Results:
Thirty eyes were included. Baseline IOP in Ologen, MMC0.4 & MMC0.2 groups were 27.43 ± 2.97, 28.4 ± 3.24, 27.56 ± 2.69 mmHg respectively. At 6 months, mean IOP in Ologen, MMC0.4 and MMC0.2 groups were 18.55 ± 3.18, 16.2 ± 3.22, 16.93 ± 3.04 mmHg respectively. Complete success was achieved in 10%, 40% & 30% respectively in Ologen, MMC0.4 and MMC0.2. No treatment group difference reported by Kaplan- Meier analysis. Shallow AC occurred more in Ologen and MMC 0.4 groups, while hypotony occurred more in MMC0.4 and 0.2 groups. A single case of suprachoroidal effusion occurred in MMC0.4 group.
Conclusions:
Ologen implant may be a promising alternative to MMC for improving success rate of trabeculectomy. Though Ologen implant provided a safer surgical profile, MMC with different concentrations achieved a lower IOP reduction.
Financial Disclosure:
NONE
